Synairgen phase 3 trials Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the first presentation of the full data analysis from its Phase 3 SPRINTER trial evaluating the efficacy and safety of SNG001 in patients hospitalised with COVID-19. Southampton, UK Synairgen CEO on funding critical Phase 2 trial for SNG001; Open Deep dive. issued in February, 2020. Synairgen reported in February this year that the international Phase III trial Synairgen PLC (AIM:SNG, OTC:SYGGF) said it is on the "verge of embarking" on a phase II trial of SNG001, for severe viral lung infection. The SPRINTER trial (SG018; NCT04732949) was a global Phase 3, randomised, placebo-controlled, double-blind, clinical trial assessing the efficacy and safety of inhaled SNG001 on top of standard of The SPRINTER trial (SG018; NCT04732949) was a global Phase 3, randomised, placebo-controlled, double-blind, multi-site clinical trial assessing the efficacy and safety of inhaled SNG001 on top of Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19. com. Southampton, UK - 21 February 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 Synairgen plc ('Synairgen' or the 'Company') Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 There were three deaths in the placebo group and none in the SNG001 group. Price target decreased to UK£2. Synairgen CEO on funding critical Phase 2 trial for SNG001 . gov NCT04518410) is a randomized, placebo-controlled, multicenter phase 2/3 adaptive platform trial for the evaluation of therapeutics for adult Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial . 3% during trading on Monday . Then Synairgen’s study arm was paused as the The COVID-19 Phase II study (SG016) Synairgen’s placebo-controlled Phase II trial evaluated SNG001 for the prevention of severe lower respiratory tract (LRT) illness caused by SARS-CoV-2 Synairgen plc Provides Update on SNG001 in the ACTIV-2 Phase 3 Trial for COVID-19 and on SNG001 Activity Against Delta and Omicron Variants Mar 04. Synairgen's primary focus is the development of its investigational inhaled interferon beta product SNG001 to meet the significant unmet need for the treatment of severe viral lung infections in mechanically ventilated Southampton, UK - 5 September 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces its collaboration on the UNIVERSAL trial, an observational study being led by the Clinical Trials Unit of the Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19 - Business Wire. Phase 3 trials will address these issues through randomisation of larger and more heterogeneous groups. For further enquiries, please contact: The topline data from Synairgen's Phase 3 clinical programme evaluating SNG001 in patients across 17 countries was announced in February 2022 and The SPRINTER trial (SG018; NCT04732949) was a global Phase 3, randomised, placebo-controlled, double-blind, clinical trial assessing the efficacy and safety of inhaled SNG001 on top of standard of care (SOC) for the treatment of adults hospitalised due to COVID-19 requiring treatment with supplemental oxygen by mask or nasal prongs. September 30, 2022 | marketwatch. Additional data from A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19. Methods. They also SNG001 was also found to have a favourable safety profile and was well tolerated in the trial subjects. University of Southampton professor and trial chief investigator Tom Wilkinson said: “Expansion of the SG016 placebo Synairgen, UK: 40,-43: Vazegepant (BHV-3500) Intranasal: Phase 2 and 3 (NCT04346615) Biohaven Pharmaceuticals, Inc, US: 44,-46: TD-0903 (JAK inhibitor) Covis Pharma, Luxembourg. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Southampton, UK ACTIV-2 is an adaptive Phase 2/3 trial testing agents in non-hospitalised adults experiencing mild to moderate COVID-19 sponsored by NIAID, part of the National Institutes of Health, and is led by The SPRINTER trial (SG018; NCT04732949) was a global Phase 3, randomised, placebo-controlled, double-blind, multi-site clinical trial assessing the efficacy and safety of inhaled SNG001 on top of standard of care for the treatment of adults hospitalised due to COVID-19 requiring treatment with supplemental oxygen by mask or nasal prongs. Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial The vast majority of Home Cohort patients experienced mild disease - only two patients were hospitalised during the treatment period, Synairgen News Headlines. Latest news . The secondary endpoints looked at The funds will enable Synairgen to advance a phase II trial of SNG001 in mechanically ventilated patients with respiratory viral infections. A place to discuss all things biology! We welcome people and content from all related fields. Southampton, UK - 13 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that the first patient has been dosed in the UK as part of its global Phase III trial (SG018) evaluating Synairgen's inhaled formulation of interferon beta-1a (SNG001), for the treatment of hospitalised COVID-19 Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial . The ideal administration timing for the Phase III Synairgen nebulised SNG001 (interferon beta-1a) asset may prove challenging to evoke the best efficacy and safety in hospitalised Covid-19, experts say. However, the company says it own phase 3 Sprinter study of SNG001 in hospitalised Covid-19 patients is progressing well, with (Sharecast News) - Synairgen announced on Monday that the international phase 3 trial of its SNG001 antiviral inhalation in patients hospitalised with Covid-19 did not meet its primary or key We look forward to tracking the progress of the ACTIV-2 trial alongside our other COVID-19 trials. The SG015 trial is a two-phase study that aims to evaluate the Synairgen has launched two studies of SNG001 for at-risk Covid-19 patients; one is an at-home virtual trial in those at earlier stages of the disease. COVID-19 Clinical Trial Synairgen’s Phase II trial in COVID-19 patients (SG016), expected to commence imminently, will be a double-blind, placebo-controlled trial, with the pilot phase study involving 100 COVID-19 patients, across a number of NHS trusts. Analysts submissions Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2COVID-19 Trial Southampton, UK - 20 October 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad- spectrum anti-viral protein interferon beta (IFN-beta) for the treatment of severe Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Reports that Activ has recommended its SNG001 anti-viral lung treatment to progress to stage 3 trials in mild Synairgen is a University spin-off and public limited company (plc) [2] [1] The Phase 3 SPRINTER trial (SG018), a randomised, double-blind, placebo-controlled study evaluating SNG001 for the treatment of hospitalised COVID-19 patients, was initiated in January 2021. Synairgen plc the respiratory drug discovery and development company, has announced that the first patient has been dosed in the UK as part of its global Phase III trial (SG018) evaluating Synairgen’s inhaled formulation of interferon beta-1a (SNG001), for the treatment of Synairgen plc (‘Synairgen’ or the ‘Company’) £11. Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive's Stephen Gunnion about the company's fundraising We would like to show you a description here but the site won’t allow us. INEXAS clinical trial update from Pharmaxis and Synairgen have revised their Lysyl Oxidase type 2 enzyme (LOXL2) program collaboration agreement, after obtaining positive results in preclinical studies and launching a Phase 1 clinical trial. Intraday This provided the rationale for the current phase III study (SPRINTER; SARS-CoV-2: Phase III TRial of Inhaled INTERferon-β Therapy), the sponsor of this trial; and owns shares in Synairgen plc, the parent company of the sponsor of this trial. Live SNG RNS. A total of 623 patients were randomised to receive SNG001 (n=309) or placebo (n=314) in addition to standard of care (SOC). The double-blind Synairgen Regulatory News. Southampton, UK . Earlier this year, Synairgen announced that the Phase-III Sprinter trial did not meet the primary endpoint of patient recovery and subsequent hospital discharge. The drug is already widely Shares in Southampton, England-based Synairgen shot up nearly 30% on largely positive mid-stage trial data for its experimental therapy SNG001, which is designed to help protect asthma patients from respiratory infections. PureTech is committed to advancing the program to Phase 3 and intends to discuss the Phase 2b results with regulatory authorities to align on the appropriate path forward. The first patient received the treatment at Hull Royal This was a smaller, pilot study and the next step will be to assess the data. UK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after encouraging topline results from a phase 2 study that started last March. with its drug pipeline, therapeutic area, technology platform, 10 clinical trials, 1 news, and 15 literature, Disease Domain:Infectious Diseases, Technology Platform:Monoclonal antibody, Drug:BMS-986414, Interferon beta 1a(The University of Synairgen plc discovers and develops drugs for respiratory diseases. The biotech company’s valuation was justified by its ongoing phase III trial into its novel ‘SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon Phase 2 studies in ACTIV-2 enroll up to 220 volunteers, while exact enrollment size of Phase 3 studies will vary depending on mode of administration of the investigational agent. 1 million) as expenditure on the Phase 3 SPRINTER trial, substantially completed in 2022, decreased and manufacturing activities reduced. The adaptive nature of the ACTIV Synairgen's drug trial was the template for the Accord programme, a fast-track clinical trial scheme set up by the UK government in April to accelerate the development of new drugs for patients ACTIV-2/A5401 (ClinicalTrials. These patients face mortality rates of 25% to 45%, and However, Synairgen shares have now recovered to 26p, as a home-based trial could still yield results. Phase 3 clinical trials, also known as phase iii Synairgen plc | 2,477 followers on LinkedIn. Funding: Synairgen Research. Methods: Safety, clinical and antiviral efficacy of inhaled interferon-β1a (SNG001) were evaluated in a phase II randomized Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive's Stephen Gunnion about the company's fundraising efforts to support a pivotal Phase 2 clinical trial. Analyses of several trials conducted by Synairgen to date reveal that, across different patient populations and care settings, those with more severe disease at the start of treatment responded best to treatment with SNG001. Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive's Stephen Gunnion about the company's fundraising Synairgen COVID-19 treatment advances to Phase 3 trial SNG001 delivers an inhaled formulation of Interferon-beta-1a directly to the lungs Synairgen plc ('Synairgen' or the 'Company')Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 Southampton, UK - 21 February 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the Synairgen said that the first patient has been dosed in the Phase 3 SG018 trial of its SNG001 inhaled interferon beta-1a in hospitalized COVID-19 patients, with the SG018 study expected to enroll 610 COVID-19 patients at sites in 20 countries. 20 Synairgen plc is covered by 3 analysts. Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial . Further analysis of the SPRINTER trial data will be presented at the ATS 2022 International Conference, being held between 13-18 May 2022 in San Francisco. October 4, 2022 | businesswire. Search. Posting of Report and Accounts and Notice of AGM. 04). The drug development process will normally proceed through all four phases over many years. "SNG001 is an investigational drug currently in Phase 3 trials, with the first data read out early in 2022, and contains the essential antiviral protein interferon beta, a protein that 'switches In November 2021, Synairgen announced that it had completed enrolment of 610 patients in its Phase 3 SPRINTER trial (SG018) and expects top-line data early this year. 0 million to advance a large Phase 2 trial in patients requiring mechanical ventilation due to respiratory viral infections. . SNG001 has also recently Free Online Library: Coronavirus: Synairgen starts final phase of treatment trials days after UK introduces new regimen. Synairgen and its clinical advisors believe that the data warrants additional analysis in a platform trial, which the company is currently studying. Stage 2: To confirm the efficacy of candidate agents selected on the basis of evidence from Stage 1 in patients hospitalised with COVID-19 in an expansion stage. Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive's Stephen Gunnion about the company's Has no revenue either year, but research and development spending is reduced to GBP3. The company’s initial approach was to set up a Phase Synairgen PLC (AIM:SNG, OTC:SYGGF) said it is on the "verge of embarking" on a phase II trial of SNG001, for severe viral lung infection. This randomised, double-blind, placebo-controlled, multi-centre, phase 2, pilot clinical trial was done in patients . The focus will be Synairgen began its phase 3 trial in January 2021. Synairgen CEO on funding phase 2 trial for SNG001 - ICYMI 2 weeks, 3 days ago. SNG Share News. The company traded as high as GBX 3 ($0. Richard Marsden, CEO of Synairgen, said: "We are delighted to have secured a path forward for SNG001 with the conditional raise of £18. Synairgen has announced that the first patient has been dosed in the UK a part of a global Phase III trial evaluating the inhaled formulation of interferon beta-1a , for the treatment of hospitalised This phase 3 vaccine trial is testing the safety and effectiveness of a two-dose regimen of a new COVID-19 vaccine, which uses a weakened common cold virus and a part of the COVID-19 virus to stimulate the immune system to later fight a real infection. 7% reduction in Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial . This represents a ~90% relative risk reduction, a comparable reduction to that seen with Paxlovid in Phase 3 trials The trials of Synairgen's inhaled drug as a treatment for COVID-19 are going global. [15] Methods: We did a randomised, double-blind, placebo-controlled, phase 2 pilot trial at nine UK sites. Menu. Outside the trial, he declares payment or honoraria from Regeneron, GlaxoSmithKline and Kymab. 5 million from GBP11. 1 Richard Marsden, CEO of Synairgen, said: “We are delighted to have secured a path forward for SNG001 with the conditional raise of £18. Credit: Shutterstock. Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001)is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial . Synairgen plc the respiratory drug discovery and development company, has The SPRINTER trial (SG018; NCT04732949) was a global Phase 3, randomised, placebo-controlled, double-blind, multi-site clinical trial assessing the efficacy and safety of SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA) and the Phase 3 SPRINTER trial was deemed an Urgent Public Health Southampton, UK – 20 October 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum anti-viral Synairgen's SG018 Phase 3 trial is a randomised, double-blind, placebo-controlled study being conducted in 17 countries. [1] When expressed specifically, a clinical trial phase is capitalized both in name and Roman numeral, such as "Phase I" clinical trial. Phase 3 clinical trials - Large-scale testing. A 52-week phase 2 study of itepekimab, a monoclonal antibody directed against IL-33, in 343 patients with COPD with two or more exacerbations in the previous year showed a non-significant 19% reduction Press View all press releases Subscribe to news 2024. Synairgen’s Sprinter Trial. In a Phase 2 trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than two-fold chance of recovery to 'no limitation of activities' versus placebo. The trial design has changed from that published on clinicaltrials. A large-scale trial of a new treatment it is hoped will help stop Covid-19 patients from developing severe illness has begun in the UK. Depending on the results, this trial may be expanded in the future. Trial design ACCORD Synairgen’s Phase II trial in coronavirus (Covid-19) patients is a double-blind, placebo-controlled study. Data from the phase 3 trial could provide a much-needed tiebreaker on the efficacy of the treatment, which so far has had a mixed bag of results. There was, however, an encouraging signal in the key secondary endpoint of reduction in the relative risk (RRR) of progression to severe disease or death within 35 days including a 25. Southampton, UK – 20 October 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum anti-viral Synairgen has reported that results from the home cohort of its SG016 Phase II clinical trial of inhaled SNG001 demonstrated a reduction in the rate of hospitalisation in Covid-19 patients. The inhaled Synairgen announced in February 2022 that the Phase 3 SPRINTER trial did not meet the primary endpoints of discharge from hospital and recovery. [1]If the drug successfully passes through Phases I, II, Southampton, UK – 8 September 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces positive data from the interim analysis of its exploratory Synairgen has dosed the first patient in a Phase II trial of inhaled SNG001 for the treatment of patients with chronic obstructive pulmonary disease (COPD). Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, UK Synairgen's Phase 3 clinical programme is currently evaluating SNG001 in patients across 17 countries. Due to an urgency to deliver a trial result in the setting of the COVID-19 pandemic, patient follow-up was Synairgen ’ s share price fell off a cliff in February after the company posted disappointing results from its phase 3 “sprinter” trial of SNG001, an inhalation treatment. Once the final patients have completed the initial 35-day trial period Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial . " Efficacy . Synairgen share price: trials and tribulations. We are a specialist respiratory biotech company focused on severe viral lung infections | Synairgen is a specialist respiratory biotech company whose primary focus is developing its investigative inhaled IFN-β candidate for the treatment of severe viral lung infections as potentially the first host-targeted broad-spectrum antiviral COVID-19 Phase II trial – SG016 Synairgen's Phase II clinical trial in COVID-19 patients, SG016, was a double-blind, placebo-controlled trial. with confirmed SARS-CoV-2 infection and Explore Synairgen Research Ltd. To date, the company has not received any data from the Activ-2 trial. Synairgen News Headlines. The SPRINTER trial (SG018; NCT04732949) is a global Phase 3, randomised, placebo-controlled, double-blind, multi-site clinical trial assessing the efficacy and safety of The SPRINTER trial (SG018; NCT04732949) was a global Phase 3, randomised, placebo-controlled, double-blind, clinical trial assessing the efficacy and safety of inhaled Synairgen began a placebo-controlled Phase 2 trial in COVID-19 patients in the UK in March 2020. Once the final patients have completed the initial 35-day trial In March 2022, due to the need to modify the study design in light of the emergence of the Omicron variant of SARS-CoV-2, the US National Institutes of Health (NIH) ACTIV-2 trial team asked Synairgen to temporarily pause preparation activities for ACTIV-2 Phase 3 until the timeline for the activation of SNG001 in the trial could be clarified. Study design and participants. These patients are severely ill and face mortality rates of between 25% to 45%. Due to an urgency to deliver a trial result in the setting of the COVID-19 pandemic, patient follow-up was completed at 28 days, a timepoint at which, interestingly, some of the greatest treatment effects of SNG001 on recovery were observed. These patients face mortality rates of 25% to 45%, and the company aims to demonstrate the treatment’s potential to significantly reduce these rates. The two cohort 221 patient trial comprised 101 patients randomised in the hospital setting (initial results reported 20 July with further analyses announced in September 2020), and a further 120 Synairgen PLC - Southampton, England-based respiratory company developing SNG001 treatment, containing the broad-spectrum antiviral protein interferon beta - Publishes results of Sprinter phase 3 UK biotech Synairgen has started dosing patients in its phase 2 trial of SNG001, an inhaled formulation of interferon beta-1a that aims to treat coronavirus infections. Shares in Southampton, England-based Synairgen shot up nearly 30% on largely positive mid-stage trial data for its Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive's Stephen Gunnion about the company's fundraising efforts to support a pivotal Phase 2 clinical trial. Strong evidence suggests that LOXL2 contributes to the formation of scar tissue (fibrosis), which can harden and irreparably damage the lungs. Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive's Stephen Gunnion about the company's fundraising efforts to support a pivotal Phase 2 clinical trial. This trial investigated the safety, efficacy and tolerability of SNG001 in patients hospitalized with COVID-19 and required supplemental oxygen treatment. Based on the results of the Phase 2 trial, the company initiated a Phase 3 trial in January 2021 which ultimately included 17 UK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after encouraging topline results from a phase 2 study that Synairgen plc announced that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary The trials of Synairgen's inhaled drug as a treatment for COVID-19 are going global. ” As announced by Synairgen on 25 January 2021, ACTIV is a public-private partnership to develop Synairgen have published a press release today announcing the data from their phase II trial of inhaled interferon beta (IFN-beta) in COVID-19 patients. 205,983 shares randomized, double-blind, placebo-controlled, phase 2 trial of nebulized orally-inhaled SNG001 in adult out-patients with mild-to-moderate COVID-19. A Phase 2 study of SNG001 in non-hospitalized patients is also underway, the company said. 1M subscribers in the biology community. Dr Penny Ward, Faculty of Pharmaceutical Medicine, Visiting Professor in 16%),17 Synairgen (NCT04385095) (n=10, 12%),18 TACTIC (NCT04390464) (n=4, 5%),19 Theravance Platform and adaptive designs used in phase 2 and 3 trials were also almost universally recommended, since these were seen to enable rapid evolution of thera- UK biotech Synairgen saw the value of its shares crater after its inhaled interferon beta therapy SNG001 was found to provide no benefit to people hospitalised with COVID-19. Southampton, UK - 12 October 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announced today that it has received the following INEXAS clinical trial update from AstraZeneca (AZ) relating to AZD9412, inhaled interferon beta, a programme developed by Synairgen and licensed to AZ in June 2014. Proposed Fundraising to raise a minimum of £18 million and a maximum of £19 million 20th December 2024; Results of AGM and Appointment of New Chairman 10th October Status: Synairgen said July 20 that SNG001 generated positive results in the Phase II SG016 trial (NCT04385095), which assessed the inhaled drug in hospitalized COVID-19 patients. 04) and last traded at GBX 3 ($0. SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation – INF-beta is a naturally occurring protein that controls Synairgen CEO on funding critical Phase 2 trial for SNG001 . Pitted against the current standard of care, SNG001 missed the primary and three key secondary endpoints. 1 Year Synairgen Chart. PT. The drug Clinical Trials. Synairgen Shares Drop Amid Phase 3 Study Issues; Pretax Loss Narrows - MarketWatch. At the close on 26 September, the stock was down If both phase 2a and 2b are successful and researchers gain the information they need, the clinical trial can move on to phase 3. 1. Covis announces initiation of Phase 3 US trial of Alvesco ciclesonide MDI for the treatment of COVID-19. Financial News Articles for Synairgen Plc Ord 1p updated throughout the day. Following the original SG016 trial, investigating SNG001, Synairgen has commenced a Phase III randomised placebo-controlled trial of SNG001 in hospitalised COVID-19 patients, named SG018. Southampton, UK – 18 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that Simon Shaw Synairgen plc (LON:SNG – Get Free Report)’s share price shot up 33. It develops SNG001, inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-Ã ), which Parexel announced that Synairgen has signed a collaboration agreement with Parexel Biotech for a Phase 3 trial of Synairgen’s SNG001 nebulized interferon-beta-1a for the treatment of COVID-19. Southampton, UK – 20 October 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum anti-viral Synairgen plc (' Synairgen ' or the 'Company') Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 . In July 2020, Synairgen announced positive results from a Phase 2 trial of SNG001 in COVID-19 patients hospitalized in the UK. It has been adopted by the NIHR Respiratory Translational Research Collaboration which is TW reports being a founder and director of, and a shareholder in, my mhealth, outside of the submitted work; receiving research grants for trials of interferon beta and other COVID-19 treatments from AstraZeneca, GlaxoSmithKline, Synairgen, Bergenbio, UCB, NIHR, UKRI, and my mhealth within the submitted work; receiving consultancy fees from Clinical trials testing potential medical products are commonly classified into four phases. 9 million), with the reduction being Following the Phase 3 SPRINTER trial result, Synairgen has been consulting with experts and has, as a result, brought the clinical opportunity and Synairgen's priority into clear focus: to unlock the full potential of SNG001 to the benefit of patients by further investigating its efficacy in patients hospitalised due to a range of viruses Richard Marsden, CEO of Synairgen, said: "We are delighted to have secured a path forward for SNG001 with the conditional raise of £18. Synairgen's SG018 Phase 3 trial is a randomised, double-blind, placebo-controlled study being conducted in 17 countries. The focus will be Synairgen News Headlines. SPRINTER: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Determine the Efficacy and Safety of Inhaled Interferon Beta-1a (SNG001) for the Treatment of Patients Hospitalised Due to COVID-19 (NCT04732949) Science 3. Background: With the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited global access to therapeutics, the evaluation of novel therapeutics to prevent progression to severe COVID-19 remains a critical need. 1 million (30 June 2022: £2. Regulatory News Articles for Synairgen Plc Ord 1p Synairgen has announced that the first patient has been dosed in the UK a part of a global Phase III trial evaluating the inhaled formulation of interferon beta-1a , for the treatment of hospitalised Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Reports that Activ has recommended its SNG001 06/01/2023 04:54:50 Cookie Policy +44 (0) 203 8794 460 Free Membership Login Synairgen's inhalable therapy has failed in late-stage trial testing in patients hospitalised with COVID-19, wiping out over 85% of the British drugmaker's stock value on Monday after the blow to " In the meantime, we eagerly await the Phase 2 data from the US NIH ACTIV-2 trial in home- based COVID-19 patients, and that trial's larger, follow-on Phase 3 study, as part of the development path for SNG001. The funds will primarily be used to enable Synairgen to progress with Phase III clinical trials in COVID-19 patients, Its results in its Phase II trial in UK hospitalised COVID-19 patients earlier this year were promising and Synairgen plc Exercise of Share Options and Total Voting Rights: 10/10/2024: 16:05: UK RNS: Synairgen plc Results of AGM and Appointment of New Chairman: Synairgen slashes costs and focuses on small hospital trials: 27/6/2024: 06:00: UK RNS: Synairgen plc 2023 Full Year Results: More Synairgen News. Adults aged 18 years or older and admitted to hospital with COVID-19 symptoms, with a positive RT-PCR or point-of-care test, or both, were randomly assigned (1:1) to receive SNG001 (6 MIU) or placebo by inhalation via a mouthpiece daily for 14 The funds will enable Synairgen to advance a phase II trial of SNG001 in mechanically ventilated patients with respiratory viral infections. gov NCT04518410) is a randomized, placebo-controlled, multicenter phase 2/3 adaptive platform trial for the evaluation of therapeutics The Phase III trial by Synairgen is recruiting patients who require oxygen therapy via nasal prongs or mask. Interpretation: Patients who received SNG001 had greater odds of improvement and recovered more rapidly from SARS-CoV-2 infection than patients who received placebo, providing a strong rationale for further trials. Southampton, UK - 21 February 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today Synairgen plc (‘Synairgen’ or the ‘Company’) Appointment of New Chairman. Administrative expenses for the six months ended 30 June 2023 were £2. Synairgen CEO Richard Marsden said: “While we are disappointed by the overall outcome, SNG001 has been Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing. Methods Trial design and oversight ACTIV-2/A5401 (ClinicalTrials. gov and the data presented are from a revised phase II trial in 100 patients hospitalised with COVID-19. SNG001 is a formulation with Objectives Stage 1: To evaluate the safety and efficacy of candidate agents as add-on therapies to standard of care (SoC) in patients hospitalised with COVID-19 in a screening stage. The design of this trial was based on the WHO R&D Blueprint Novel Coronavirus COVID-19 Therapeutic Trial Synopsis. 1 million, as phase 3 Sprinter trial of SNG001 is mostly completed in 2022. 16. Southampton, UK Synairgen CEO on funding critical Phase 2 trial for SNG001 . Marsden explained that the trial will enrol 450 patients and focus on reducing mortality “Synairgen have released the first analysis of the SG016 trial of inhaled interferon-beta-1a (SNG001) in patients in a press release this morning. by "Proactive Investors United Kingdom"; Biological response modifiers Clinical trials Coronaviruses COVID-19 Drug therapy Interferon Product development Sarilumab Synairgen CEO on funding critical Phase 2 trial for SNG001 . qpldm awavz xnnhn rhvg xlbbg wmy chdee grb awzfidv llynb